Nakamura Diane S, Edwards Andrew K, Ahn Soo Hyun, Thomas Richard, Tayade Chandrakant
Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Canada.
Department of Obstetrics and Gynecology, Queen's University, Kingston, Canada.
PLoS One. 2015 Mar 26;10(3):e0121545. doi: 10.1371/journal.pone.0121545. eCollection 2015.
Endometriosis is a gynecological disease defined by the growth of endometrium outside of the uterus. Although endometriosis contributes to 50% of female infertility cases, medical treatments are incompatible with pregnancy. Angiogenesis, the growth of blood vessels from existing vasculature, plays a crucial role in endometriotic lesion growth and survival. Previously, we demonstrated the effectiveness of thrombospondin-1 analog, ABT-898 (Abbott Laboratories) to inhibit endometriotic lesion vascularization in mice. We have now evaluated the trans-generational implications of ABT-898 treatment before and during mouse pregnancy. We hypothesized that ABT-898 would target lesion vasculature without affecting pregnancy, offspring development, or ovarian and uterine vascularity in mice. Endometriosis was induced using human endometrium in β-estradiol-primed BALB/c-Rag-2-/-Il2rγ-/- mice receiving intraperitoneal injections of ABT-898 (25 mg/kg) or 5% dextrose control for 21 days. Ultrasound assessment of lesion vascularization revealed a reduction in blood flow supplying treated lesions. Excised ABT-898 treated lesions stained for CD31+ endothelial cells exhibited a decrease in microvessel density. Following confirmation of estrous cycling, mice were bred and treated with ABT-898 on gestation days 7, 9, 11, 13, 15, 17, and 19. ABT-898 did not affect estrous cycling or pregnancy parameters including litter size across generations and offspring weight gain. Quantification of angiogenic cytokine plasma levels revealed no significant differences between treatment groups. Vimentin staining of the uterus and ovary revealed no observable effects of ABT-898. Similarly, no obvious histological anomalies were observed in the kidney, liver, ovary, or uterus following ABT-898 treatment. These results suggest that ABT-898 effectively inhibit endometriotic lesion vascularization without affecting trans-generational pregnancy outcomes in mice.
子宫内膜异位症是一种妇科疾病,其定义为子宫内膜在子宫外生长。尽管子宫内膜异位症导致了50%的女性不孕病例,但药物治疗与怀孕不相容。血管生成,即从现有脉管系统生长出新的血管,在子宫内膜异位症病变的生长和存活中起着关键作用。此前,我们证明了血小板反应蛋白-1类似物ABT-898(雅培实验室)在抑制小鼠子宫内膜异位症病变血管形成方面的有效性。我们现在评估了在小鼠怀孕前和怀孕期间使用ABT-898治疗的跨代影响。我们假设ABT-898将靶向病变血管,而不影响小鼠的怀孕、后代发育或卵巢和子宫的血管形成。在接受腹腔注射ABT-898(25mg/kg)或5%葡萄糖对照21天的经β-雌二醇预处理的BALB/c-Rag-2-/-Il2rγ-/-小鼠中,用人子宫内膜诱导子宫内膜异位症。对病变血管形成的超声评估显示,供应治疗病变的血流减少。对切除的经ABT-898治疗的病变进行CD31+内皮细胞染色,显示微血管密度降低。在确认发情周期后,小鼠进行交配,并在妊娠第7、9、11、13、15、17和19天用ABT-898治疗。ABT-898不影响发情周期或怀孕参数,包括各代的窝仔数和后代体重增加。血管生成细胞因子血浆水平的定量分析显示治疗组之间无显著差异。子宫和卵巢的波形蛋白染色显示ABT-898没有可观察到的影响。同样,在ABT-898治疗后,在肾脏、肝脏、卵巢或子宫中未观察到明显的组织学异常。这些结果表明,ABT-898有效地抑制了子宫内膜异位症病变的血管形成,而不影响小鼠的跨代怀孕结果。